Singh S, Singh R, Kaul A, Goel A. Hepatitis B and chronic kidney disease: Bench to bedside. World J Nephrol 2025; 14(4): 109767 [DOI: 10.5527/wjn.v14.i4.109767]
Corresponding Author of This Article
Amit Goel, Professor, Department of Hepatology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Raebareli Road, Lucknow 226014, Uttar Pradesh, India. agoel.ag@gmail.com
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Minireviews
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Dec 25, 2025 (publication date) through Dec 23, 2025
Times Cited of This Article
Times Cited (0)
Journal Information of This Article
Publication Name
World Journal of Nephrology
ISSN
2220-6124
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Share the Article
Singh S, Singh R, Kaul A, Goel A. Hepatitis B and chronic kidney disease: Bench to bedside. World J Nephrol 2025; 14(4): 109767 [DOI: 10.5527/wjn.v14.i4.109767]
World J Nephrol. Dec 25, 2025; 14(4): 109767 Published online Dec 25, 2025. doi: 10.5527/wjn.v14.i4.109767
Hepatitis B and chronic kidney disease: Bench to bedside
Surender Singh, Rajani Singh, Anupma Kaul, Amit Goel
Surender Singh, Rajani Singh, Amit Goel, Department of Hepatology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow 226014, Uttar Pradesh, India
Anupma Kaul, Department of Nephrology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow 226014, Uttar Pradesh, India
Author contributions: Singh S contributed to review of literature, manuscript writing and editing; Singh R contributed to manuscript writing; Kaul A contributed to manuscript editing; Goel A contributed to conceptualization, review of literature, manuscript writing and editing.
Conflict-of-interest statement: All authors declare that they have no conflict of interest to disclose.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Amit Goel, Professor, Department of Hepatology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Raebareli Road, Lucknow 226014, Uttar Pradesh, India. agoel.ag@gmail.com
Received: May 21, 2025 Revised: August 17, 2025 Accepted: November 27, 2025 Published online: December 25, 2025 Processing time: 216 Days and 15.9 Hours
Abstract
Chronic kidney disease (CKD) has an intricate relationship with hepatitis B virus (HBV) due to impaired immune status and repeated risk for HBV exposure in people with CKD. Extensive discussion is required on issues related to disease burden, progression of acute HBV infection to chronic infection, impaired immune response to the hepatitis B vaccine, optimal vaccination schedules and strategies, etc. In this review, we attempted to summarize the updated existing knowledge on these topics. In addition, the implication of HBV in the pathogenesis of glomerular disease is also discussed. This review extensively focused on issues related to hepatitis B vaccine induced immune response in CKD patients—serological and cell-mediated immune responses to the vaccine, with particular emphasis on effect of CKD stages on vaccine response, newer types of hepatitis B vaccines for non-responders, revaccination strategies, and the durability of vaccine-induced immunity. We also discussed the literature on risk of HBV transmission following organ from hepatitis B surface antigen (HBsAg)-positive donors, along with perioperative management when the donor is HBsAg-positive but the recipient is HBsAg-negative.
Core Tip: Hepatitis B virus (HBV) infection is prevalent in chronic kidney disease (CKD) patients, particularly those on hemodialysis. Vaccination against hepatitis B is recommended for all those with CKD. Highly effective oral antiviral drugs with a strong barrier to resistance are available for HBV treatment but they require dose adjustment based on a patients' creatinine clearance. Given the ever-increasing number of patients with CKD and HBV, it is crucial to raise awareness regarding its modes of transmission, prevention strategies, and available treatment modalities.
